Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy
Authors:
- 29 August 2022
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (3) , 667-678
Abstract
IL-1α and IL-1β are both involved in several aspects of tumor biology, including tumor initiation, progression, metastasis, and not least in resistance to various therapies. IL-1α can function as an alarmin to signal cellular stress, and acts to induce downstream events, including production of IL-1β, to amplify the signal. Both IL-1α and IL-1β act through the same receptor complex, IL-1R1-IL1RAP, to mediate signal transduction. IL1RAP is expressed on tumor cells and in the tumor microenvironment by for example CAF, macrophages and endothelial cells. The anti-IL1RAP antibody nadunolimab (CAN04) inhibits both IL-1α and IL-1β signaling and induces ADCC of IL1RAP-expressing tumor cells. As both IL-1α and IL-1β mediate chemoresistance, the aim of this study was to explore the potential synergy between nadunolimab and chemotherapy. This was performed using the NSCLC PDX model LU2503 and the syngeneic MC38 model, in addition to in vitro cell line experiments. We show that chemotherapy induces expression and release of IL-1α from tumor cells and production of IL-1β-converting enzyme, ICE, in the tumor stroma. IL-1α is also demonstrated to act on stromal cells to further induce the secretion of IL-1β, an effect disrupted by nadunolimab. Nadunolimab, and its surrogate antibody, synergize with platinum-based as well as non-platinum-based chemotherapy to induce potent anti-tumor effects, while blockade of only IL-1β signaling by anti-IL-1β antibody does not achieve this effect. In conclusion, blockade of IL1RAP with nadunolimab reduces IL-1-induced chemoresistance of tumors.Keywords
Funding Information
- Cantargia AB
This publication has 38 references indexed in Scilit:
- The Interleukin-1α Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of CytokinesFrontiers in Immunology, 2013
- Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from naïve Asian NSCLC patientsInternational Journal of Cancer, 2012
- Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory proteinProceedings of the National Academy of Sciences, 2010
- Cancer cell‐derived IL‐1α promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cellsJournal of Surgical Oncology, 2010
- Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammationProceedings of the National Academy of Sciences, 2010
- Tumor‐stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7International Journal of Cancer, 2009
- Immunological and Inflammatory Functions of the Interleukin-1 FamilyAnnual Review of Immunology, 2009
- Emerging roles of caspase-3 in apoptosisCell Death & Differentiation, 1999
- The Interleukin-1 Receptor Accessory Protein (IL-1RAcP) Is Essential for IL-1-induced Activation of Interleukin-1 Receptor-associated Kinase (IRAK) and Stress-activated Protein Kinases (SAP Kinases)Journal of Biological Chemistry, 1997
- A critical role for interleukin‐1 receptor accessory protein in interleukin‐1 signalingEuropean Journal of Immunology, 1997